San Diego – December 6, 2016 – Cooley advised TRACON on its $17.4 million shelf-takedown of 3,018,750 shares of common stock, which included the full exercise of the underwriter’s option to purchase additional shares.
TRACON, which trades on the NASDAQ Global Market under the symbol “TCON,” is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration and fibrotic diseases.
Cooley advised TRACON on its recent strategic licensing collaboration with Janssen Pharmaceutical, as well as its IPO in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.